Axis Direct Assigns Buy Ratings to Three Indian Healthcare Stocks

Axis Direct assigned Buy ratings to Dr Lal PathLabs, Vijaya Diagnostic Centre and Nephrocare Health Services, with target prices implying up to 21% upside.